Glox Therapeutics
PrivateLast Round
Grant
Jan 21, 2025
Total Funding Raised
$7.24M
Company Overview
Glox Therapeutics is a biotechnology company developing a pipeline of engineered precision bacteriocins targeting pathogens that cause serious infections associated with high levels of antimicrobial resistance (AMR).
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Glox Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Glox Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jan 21, 2025 | ||||
| Grant | Nov 20, 2024 | ||||
| Seed | Nov 14, 2023 |
Key People
Founding team and executive leadership
Glox Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| PACE (Pathways to Antimicrobial Clinical Efficacy) | Grant |
| LifeArc | Grant |
| Boehringer Ingelheim Venture Fund | Seed |
| Scottish Investment Bank (Scottish Enterprise) | Seed |
| CF AMR Syndicate | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 19, 2025
Grew 63% QoQ, from 8 to 13 employees.
- Jun 6, 2025
Grew 50% QoQ, from 8 to 12 employees.
Glox Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Glox Therapeutics's valuation, stock price, and market status.